DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. FDA–2010–N–0001]

Office of Women’s Health Update

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of meeting.

The Food and Drug Administration (FDA) is announcing the following meeting: Office of Women’s Health (OWH) Update. The topics to be discussed are OWH current and future activities in the areas of women’s health research and educational outreach.

Date and Time: The meeting will be held on Wednesday, September 22, 2010, 8:30 a.m. to 10 a.m.

Location: The meeting will be held at the Cohen Building, rm. 5051, 330 Independence Ave. SW., Washington, DC 20201.

Contact: Deborah L. Kallgren, Office of Women’s Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 2314, Silver Spring, MD 20932-0002, 301-796-9442, FAX: 301-847-8604, email: deborah.kallgren@fda.hhs.gov.

Registration and Requests for Oral Presentations: There is no registration fee, but seating is limited to 20. Send registration information (including name, title, firm name, address, telephone, and fax number) to the contact person by September 13, 2010. If you need special accommodations due to a disability, please contact Deborah L. Kallgren at least 7 days in advance.


David Dorsey,
Acting Deputy Commissioner for Policy, Planning and Budget.

[FR Doc. 2010–21917 Filed 9–1–10; 8:45 am]
BILLING CODE 4162–20–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center on Minority Health and Health Disparities; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council on Minority Health and Health Disparities. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Council on Minority Health and Health Disparities.

Date: September 14, 2010.
Closed: 8 a.m. to 9:30 a.m.
Agenda: To review and evaluate grant applications and/or proposals.
Place: Doubletree Hotel and Executive Meeting Center, 8120 Wisconsin Avenue, Bethesda, MD 20814.
Open: 9:30 a.m. to 5 p.m.

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.


Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010–21916 Filed 9–1–10; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Administration for Native Americans; Notice of Meeting

AGENCY: Department of Health and Human Services, Administration for Children and Families.

ACTION: Notice of Tribal Consultation.

SUMMARY: The Department of Health and Human Services (HHS), Administration for Children and Families (ACF) will host a tribal consultation to solicit input on the agency’s draft tribal consultation policy.

SUMMARY: The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) is announcing a scientific workshop to solicit feedback on the risks and benefits associated with the long-term use of nicotine replacement therapy (NRT) products. NRT products facilitate smoking cessation by ameliorating the symptoms of nicotine withdrawal and are available as approved nonprescription and prescription drugs. No currently-approved NRT product is intended for use beyond 12 weeks to relieve the acute withdrawal symptoms experienced when quitting smoking.

Date and Time: The public workshop will be held on October 26 and 27, 2010, from 8:30 a.m. to 5 p.m.


Contacts: Mary C. Gross, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6178, Silver Spring, MD 20993–0002, 301–796–3519, email: mary.gross@fda.hhs.gov; or Dominic Chiapperino, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 3134, Silver Spring, MD 20993–0002, 301–796–1183, email: dominic.chiapperino@fda.hhs.gov.

Registration to Attend the Workshop and Requests to Participate in Open Public Hearing: If you wish to attend or testify for the open public hearing, please email your registration to NRTPublicMeeting@fda.hhs.gov by October 5, 2010. Those without email access may register by contacting one of the persons listed in the Contacts section of the document. Please provide complete contact information for each attendee, including name, title, affiliation, address, email address, and telephone number. Registration is free and will be on a first-come, first-served basis. Early registration is recommended because seating is limited. FDA may limit the number of participants from each organization as well as the total number of participants based on space limitations. Registrants will receive confirmation once they have been accepted for the workshop. Onsite registration on the day of the meeting will be based on space availability. If registration reaches maximum capacity, FDA will post a notice closing meeting registration for the workshop at: http://www.fda.gov/Drugs/NewsEvents/ucm221185.htm.

An open public hearing will be held between 1:30 p.m. to 2:30 p.m. on October 27, 2010, during which speaker testimony will be accepted. The FDA will try to accommodate all persons who wish to testify, however, the duration of each